Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Neuroblastoma Market Size Changed, over the years?

Recently, the neuroblastoma market has noted robust growth. The market is projected to expand from $2.97 billion in 2024 to $3.15 billion in 2025, manifesting a compound annual growth rate (CAGR) of 6.1%. This progress in the former period can be ascribed to a rise in the occurrence of neuroblastoma, an escalation in research and development aimed at pediatric neuroblastoma treatments, a surge in childhood cancer cases, and increasing financial backing and assistance from the government.

How Much Will the Neuroblastoma Market Be Worth in 2029?

In the coming years, the neuroblastoma market is anticipated to experience robust growth, expanding to a size of $3.93 billion by 2029, with a compound annual growth rate (CAGR) of 5.7%. The projected growth for this period can be ascribed to various factors such as enhanced government funding, an escalating number of disease occurrences, an increased emphasis on early detection, growing instance of genetic mutations, and the intensification of understanding and advances in research. Notable trends during this forecast period enclose the progression of drugs that aim at specific molecular pathways, breakthroughs in non-invasive imaging technologies, progress in gene-editing technologies, intensified attention towards individualized treatments, and the maturation of radiolabeled compounds.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp

Which is the Largest Company in the Neuroblastoma Market?

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

What Are the Main Market Drivers in the Neuroblastoma Industry?

The neuroblastoma market is predicted to experience expansion due to a rise in instances of childhood cancer. This category of cancers mostly affects children and adolescents, commonly hitting areas like the brain, blood, and bones requiring specialized treatment methodologies. Enhanced diagnostic methods, heightened awareness, environmental exposure, genetic predispositions, and advances in medical research are credited with the surge in childhood cancer incidences. Neuroblastoma treatment offers targeted solutions for this form of cancer, enabling early and effective measures that reduce recurrence possibilities and improve results for younger patients. For example, as per the American Cancer Society, it is estimated that around 9,620 children under the age of 15 will be diagnosed with cancer in the United States in 2024, a significant rise from 5,290 cases in 2023. As a result, the escalated occurrence of childhood cancer is fueling the expansion of the neuroblastoma market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp

How Is the Neuroblastoma Market Segments Structured?

The neuroblastoma market covered in this report is segmented –

1) By Product Types: Tablets, Vaccines, Other Product Types

2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types

3) By Distribution Channel: Online, Offline

4) By End-User: Hospitals, Clinics

Subsegments:

1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets

2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines

3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products

What Strategic Trends Are Transforming the Neuroblastoma Market?

Leading companies in the neuroblastoma market are concentrating on the creation of innovative therapeutic treatments, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely address cancer cells. This type of antibody is designed to target the GD2 molecule present on cancer cells while minimizing immune rejection through the integration of human elements. For example, Renaissance Pharma Ltd., a clinical-stage pharmaceutical firm based in the UK, announced the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital in August 2023. This antibody is engineered to combat newly diagnosed high-risk neuroblastoma, which is a rare and severe form of cancer affecting children. As per the agreement’s conditions, Renaissance has obtained exclusive rights to develop, manufacture, and market Hu14.18 in major international markets, including the United States, Canada, Europe, China, Japan, and Turkey.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neuroblastoma–global-market-report

Which Global Regions Offer the Highest Growth in the Neuroblastoma Market?

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901

This Report Delivers Insight On:

1. How big is the neuroblastoma market, and how is it changing globally?

2. Who are the major companies in the neuroblastoma market, and how are they performing?

3. What are the key opportunities and risks in the neuroblastoma market right now?

4. Which products or customer segments are growing the most in the neuroblastoma market?

5. What factors are helping or slowing down the growth of the neuroblastoma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model